ClinicalTrials.gg
CompletedNCT04080882Updated Aug 26, 2022Results posted

Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Platysmal Bands

A Phase 2 interventional study of AbobotulinumtoxinA dose 1 and Placebo in Platysmal Bands, sponsored by Galderma R&D. Completed at 8 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-08-26.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Interventional phase 2 study to evaluate safety and efficacy of abobotulinumtoxinA for the treatment of platysmal bands.

02

Conditions studied

  • Platysmal Bands
03

In context

Lead sponsor

Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.

Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Moderate to severe platysmal bands at maximum contraction as assessed by the Investigator using a photographic scale
  • Platysmal bands graded as Level 3 or 4 at maximum contraction as assessed by the subject using a photographic scale

Exclusion criteria

Exclusion Criteria:

  • Botulinum toxin treatment of any serotype below the lower orbital rim, in the neck or chest within 12 months prior to study treatment
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
80 participants (actual)

Study arms

  • Active comparator
    AbobotulinumtoxinA dose 1

    AbobotulinumtoxinA dose 1 injected into platysma bands

    Biological: AbobotulinumtoxinA dose 1

  • Placebo comparator
    placebo

    placebo injected into platysma bands

    Other: Placebo

  • Active comparator
    AbobotulinumtoxinA dose 2

    AbobotulinumtoxinA dose 2 injected into platysma bands

    Biological: AbobotulinumtoxinA dose 2

  • Active comparator
    AbobotulinumtoxinA dose 3

    AbobotulinumtoxinA dose 3 injected into platysma bands

    Biological: AbobotulinumtoxinA dose 3

Interventions

  • BiologicalAbobotulinumtoxinA dose 1

    Treatment of platysmal bands

  • OtherPlacebo

    Treatment of platysmal bands

  • BiologicalAbobotulinumtoxinA dose 2

    Treatment of platysmal bands

  • BiologicalAbobotulinumtoxinA dose 3

    Treatment of platysmal bands

06

What researchers measure

Primary outcomes

  1. Responder Rate at Month 1 for a Single Dose of abobotulinumtoxinA Compared to Placebo

    A responder is defined as a subject who achieves grade 1 or 2 in platysmal band severity on the Investigator Live Assessment (ILA).

    Time frame: Month 1 after treatment

07

Results

Posted Jan 22, 2021

Participant flow

Participant flow — Overall Study
MilestonePlaceboAbobotulinumtoxinA Dose 1
Started2060
Completed1858
Not completed22

Outcome measures

PrimaryResponder Rate at Month 1 for a Single Dose of abobotulinumtoxinA Compared to Placebo

A responder is defined as a subject who achieves grade 1 or 2 in platysmal band severity on the Investigator Live Assessment (ILA).

Time frame:
Month 1 after treatment
Reported as:
Count of participants · Participants
Responder Rate at Month 1 for a Single Dose of abobotulinumtoxinA Compared to Placebo
ParticipantsPlaceboAbobotulinumtoxinA Dose 1
Responder Rate at Month 1 for a Single Dose of abobotulinumtoxinA Compared to Placebo336

Adverse events

Collected over 5 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/20 (0%)0/20 (0%)7/20 (35%)
AbobotulinumtoxinA Dose 10/60 (0%)0/60 (0%)14/60 (23.3%)
Most frequent other events
Showing 10 of 13
Most frequent other events
EventPlaceboAbobotulinumtoxinA Dose 1
Injection site bruisingGeneral disorders1/205/60
DiplopiaEye disorders1/200/60
Dry EyeEye disorders1/200/60
DysphagiaGastrointestinal disorders0/203/60
Dental CariesGastrointestinal disorders1/200/60
Injection site heamorrhageGeneral disorders0/203/60
Injection site swellingGeneral disorders1/200/60
MalaiseGeneral disorders1/200/60
Viral upper respiratory tract infectinonInfections and infestations1/202/60
Musculoskeletal discomfortMusculoskeletal and connective tissue disorders1/201/60

Baseline characteristics

Due to business decision study did not proceed to enroll dose 2 or dose 3.

Age, Categorical
Age, Categorical(Participants)PlaceboAbobotulinumtoxinA Dose 1Total
<=18 years000
Between 18 and 65 years206080
>=65 years000
Age, Continuous
Age, Continuous(years)PlaceboAbobotulinumtoxinA Dose 1Total
Mean50.6 ± 8.5652.1 ± 7.7451.7 ± 7.93
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboAbobotulinumtoxinA Dose 1Total
Female205878
Male022
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboAbobotulinumtoxinA Dose 1Total
Hispanic or Latino31114
Not Hispanic or Latino174966
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboAbobotulinumtoxinA Dose 1Total
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American224
White185775
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)PlaceboAbobotulinumtoxinA Dose 1Total
United States206080
Fitzpatrick Skin Type (FST)
Fitzpatrick Skin Type (FST)(Participants)PlaceboAbobotulinumtoxinA Dose 1Total
FST I000
FST II91726
FST III52530
FST IV41519
FST V112
FST VI123
08

Study locations

8 sites
  • Galderma Research Site
    Encinitas, California 92024, United States
  • Galderma Research Site
    Encino, California 91436, United States
  • Galderma Research Site
    Boynton Beach, Florida 33472, United States
  • Galderma Research Site
    Miami, Florida 33137, United States
  • Galderma Research Site
    New Orleans, Louisiana 70115, United States
  • Galderma Research Site
    New Orleans, Louisiana 70130, United States
  • Galderma Research Site
    Baltimore, Maryland 21208, United States
  • Galderma Research Site
    New York, New York 10028, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2019 to primary completion in Dec 2019, 3 months.

Results were first posted in Jan 2021, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2019
First posted
Sep 6, 2019
StartActual
Sep 25, 2019
Primary completionActual
Dec 30, 2019
CompletionActual
Jun 4, 2020
Results first posted
Jan 22, 2021
Last update
Aug 26, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04080882
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
Sep 6, 2019
Start date
Sep 25, 2019
Primary completion
Dec 30, 2019
Completion
Jun 4, 2020
Results posted
Jan 22, 2021
Last update
Aug 26, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion